Cagent Vascular, the Wayne, PA-based company aiming to redefine balloon angioplasty with its Serration Remodeling Therapy (SRT), has closed a $41.0M Series D funding round. The capital infusion will support its mission to elevate vessel preparation and treatment outcomes for patients suffering from Peripheral Artery Disease (PAD) and Chronic Limb-Threatening Ischemia (CLTI).
Known for its Serranator® PTA Serration Balloon Catheter, the first and only angioplasty balloon featuring integrated serrations, Cagent Vascular secured investment from U.S. Venture Partners and Astoria Health Investors. The device creates controlled micro-serrations in arterial walls, designed to deliver greater lumen gain and reduced recoil in endovascular interventions.
